Daiwa Securities Group
SPRY icon

Daiwa Securities Group’s ARS Pharmaceuticals SPRY Stock Holding History

Daiwa Securities Group’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-367
Closed -$4K – 1412
2025
Q4 		$4K Hold
367
– – ﹤0.01% 1258
2025
Q3 		$4K Hold
367
– – ﹤0.01% 1226
2025
Q2 		$6K Hold
367
– – ﹤0.01% 1151
2025
Q1 		$5K Hold
367
– – ﹤0.01% 1135
2024
Q4 		$4K Hold
367
– – ﹤0.01% 1179
2024
Q3 		$5K Hold
367
– – ﹤0.01% 1171
2024
Q2 		$3K Hold
367
– – ﹤0.01% 1236
2024
Q1 		$4K Hold
367
– – ﹤0.01% 1226
2023
Q4 		$2K Hold
367
– – ﹤0.01% 1280
2023
Q3 		$1K Hold
367
– – ﹤0.01% 1274
2023
Q2 		$2K Hold
367
– – ﹤0.01% 1245
2023
Q1 		$2K Buy
+367
New +$2.82K ﹤0.01% 1225

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Daiwa Securities Group's SPRY Position: Q1 2026 in Review

Daiwa Securities Group sold out of ARS Pharmaceuticals (SPRY) in Q1 2026, closing a stake of 367 shares — an estimated $4K sold.

Daiwa Securities Group first reported a position in SPRY in Q1 2023 and held it in 12 quarters. The position peaked at $6K in Q2 2025. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Daiwa Securities Group reported no remaining ARS Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Daiwa Securities Group sold 367 ARS Pharmaceuticals shares in Q1 2026, an estimated $4K.
  • Daiwa Securities Group first reported a position in ARS Pharmaceuticals in Q1 2023 and held it in 12 quarters.
  • Daiwa Securities Group's ARS Pharmaceuticals position peaked at $6K in Q2 2025.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.